Research Title: Efficacy and Safety of Point- Of-care Procalcitonin Test to Reduce Antibiotic Exposure in VAP
NCT03982667 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2020-07-15
Summary
Several studies have shown that PCT guidance can reduce the duration of antibiotic treatment for patients with bacterial infections in the ICU, without compromising the safety outcomes. However PCT is known to be more costly than standard biomarkers that commonly use in our ICU setup. This remain the main challenge for us whether by monitoring the PCT level, it can reduce both the duration of antibiotic simultaneously reduce the total cost of the treatment for the patients. A local study addressing efficacy, safety and cost analysis of PCT-guided antibiotic therapy in severe pneumonia patients is therefore warranted. Until the results from a local study become available, the utility of PCT to guide antibiotic duration in our patient population cannot be recommended.
Conditions
- Ventilator Associated Pneumonia
Interventions
- DIAGNOSTIC_TEST
-
PCT-guided group
In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and \<0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of \< 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
Sponsors & Collaborators
-
Mohd Zulfakar Mazlan, MBBS
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-06-15
- Primary Completion
- 2020-07-01
- Completion
- 2020-07-01
Countries
- Malaysia
Study Locations
More Related Trials
-
Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis
NCT03058718 ·Status: COMPLETED ·Phase: NA
-
Procalcitonin Aided Antimicrobial Therapy vs Standard of Care
NCT06960044 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Trial of Procalcitonin in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT04682899 ·Status: UNKNOWN ·Phase: PHASE3
-
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia
NCT04334850 ·Status: COMPLETED ·Phase: NA
-
Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.
NCT04339686 ·Status: UNKNOWN
-
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
NCT01723644 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
NCT07327619 ·Status: RECRUITING ·Phase: PHASE3
-
Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia
NCT07202234 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
NCT04963764 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Effect of a Point-of-care Sputum Specimen Assay at the Emergency Department for Patients Suspected of Pneumonia
NCT04651712 ·Status: COMPLETED ·Phase: NA
-
Procalcitonin Role in Influenza Patients With Regard to Morbidity, Mortality and Antibiotic Use
NCT04171128 ·Status: COMPLETED
-
Biomarker Guided Antibiotic Treatment in Community-Acquired Pneumonia
NCT03146182 ·Status: UNKNOWN ·Phase: NA
-
Diagnostic Breath Analysis for Detection of Ventilator Acquired Pneumonia (VAP)
NCT03053258 ·Status: COMPLETED
-
Pattern and Outcomes of Chest Diseases
NCT06053528 ·Status: UNKNOWN
-
Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia
NCT01018199 ·Status: WITHDRAWN ·Phase: NA
-
Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship
NCT01972425 ·Status: COMPLETED ·Phase: NA
-
Role of CBC Parameters in Early Diagnosis of Pediatric Pneumonia
NCT06146400 ·Status: NOT_YET_RECRUITING
-
Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients
NCT02600806 ·Status: UNKNOWN ·Phase: PHASE4
-
Diagnostic Accuracy of Infection Biomarkers in the Initial Investigation of Patients With Suspected Pneumonia
NCT04652167 ·Status: COMPLETED
-
Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus
NCT04403672 ·Status: UNKNOWN
-
Implementing a Combination of Clinical Parameters, Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients
NCT03366454 ·Status: COMPLETED
-
Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia
NCT03996967 ·Status: COMPLETED
-
POC SARS-CoV-2 Diagnostic PCR Device Comparison to FDA Approved Reference PCR Test
NCT04981769 ·Status: UNKNOWN
-
Clinical Trial Assessing the Value of an Antibiotic Protocol Guided by Serum Procalcitonin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Intensive Care
NCT02521636 ·Status: UNKNOWN ·Phase: NA
-
Development a Method to Extract Antibiotic Concentration From Interstitial Lung and Epithelial Lining Fluid.
NCT03970265 ·Status: COMPLETED